A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Everolimus (Primary) ; Panobinostat (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 27 Apr 2016 Status changed from active, no longer recruiting to discontinued as toxicity seemed to outweigh the benefit.
- 03 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 16 Apr 2013 Planned end date changed from 1 Jun 2015 to 1 Jun 2018 as reported by ClinicalTrials.gov.